Biography

Tom Freeman is the Director of the Centre for Drug Use Research, an interdisciplinary centre bridging the social and life sciences at the University of Bath. He is internationally known for his research on cannabis and cannabinoids. This includes studies tracking changes in cannabis products and their association with health outcomes, novel harm reduction strategies such as the standard THC unit (similar to the standard alcohol unit), and clinical trials for the treatment for cannabis use disorder. He is currently funded by a UKRI Future Leaders Fellowship. In addition to this he co-leads the Understanding and Addressing Drug Use workpackage of the NIHR Bath Mental Health Research Group, and is deputy lead of the Drugs theme of the NIHR Policy Research Unit in Addictions. His research has generated impacts with the US National Institutes of Health Research, Health Canada, the European Union Drugs Agency, the UK National Institute of Health and Care Excellence, and the UK Advisory Council on the Misuse of Drugs.

User Information

Sector Type

University

Institution/Organisation

University of Bath

Sector

Addictions and Substance Misuse

Position/Job role

Professor

Cohort

Round 8

Research

Project Title

Reducing cannabis harms through state-of-the-art tools for quantifying use, dose-related guidelines for safer use, and evidence-based drug policy

Project Summary

Cannabis is globally the most widely used drug under international control with 209 million consumers. Almost a quarter of people who have used cannabis meet criteria for a cannabis use disorder – a problematic pattern of use causing clinically significant impairment or distress. Cannabis use disorder makes a substantial contribution to the global burden of disease (0.69 million disability adjusted life years). This has risen by 40% in the past 30 years. Reducing the harms of cannabis use is a major global challenge requiring multiple strategies. One key strategy is to promote reductions in cannabis use. However, as cannabis products and patterns of use vary widely, this strategy has been constrained by the lack of a standard unit of dose for cannabis. In response to this challenge, I recently created the “standard THC unit” (THC = ∆9-tetrahydrocannabinol; the primary intoxicating constituent of cannabis). Like the standard alcohol unit, the standard THC unit could unlock multiple strategies for reducing drug harms such as improved monitoring of use, dose-related guidelines, and policies such as minimum unit pricing. The standard THC unit can also improve surveillance of cannabis use at the population level, which can then inform evidence-based drug policy to reduce harms. My objectives are as follows:

1) To develop state-of-the-art standardised tools for quantifying cannabis use harnessing the "standard THC unit". The standard THC unit is a standardised measure of dose applied to all cannabis products and methods of use (like the standard alcohol unit) and will be validated against THC consumption measured in urine samples.

2) To estimate the ability of standard THC unit consumption levels to discriminate risk of cannabis harms. These estimates will be used to inform dose-related safer use guidelines based on standard THC unit consumption, like current alcohol guidelines (e.g., "do not regularly exceed 14 units of alcohol per week" for UK adults).

3) To establish a robust UK population surveillance framework for cannabis through (i) repeat cross-sectional population surveys to assess prevalence of cannabis use, quantity of cannabis use (standard THC units), and cannabis harms; (ii) repeat cross-sectional studies of cannabis products to quantify concentrations of THC.

4) To predict the benefits and harms of different cannabis policies in co-production with a policy maker advisory group. Mathematical modelling will be used to predict the outcomes of different cannabis policy options using repeat cross-sectional data collected in the UK and other countries with contrasting cannabis policies.

Research Interests

Behavioral Sciences, Health and Medical Humanities

Research Councils

MRC, ESRC